Unknown

Dataset Information

0

RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.


ABSTRACT: BACKGROUND:Antibody-mediated targeting of regulatory T cell receptors such as CTLA-4 enhances antitumor immune responses against several cancer entities including malignant melanoma. Yet, therapeutic success in patients remains variable underscoring the need for novel combinatorial approaches. METHODS:Here we established a vaccination strategy that combines engagement of the nucleic acid-sensing pattern recognition receptor RIG-I, antigen and CTLA-4 blockade. We used in vitro transcribed 5'-triphosphorylated RNA (3pRNA) to therapeutically target the RIG-I pathway. We performed in vitro functional analysis in bone-marrow derived dendritic cells and investigated RIG-I-enhanced vaccines in different murine melanoma models. FINDINGS:We found that protein vaccination together with RIG-I ligation via 3pRNA strongly synergizes with CTLA-4 blockade to induce expansion and activation of antigen-specific CD8+ T cells that translates into potent antitumor immunity. RIG-I-induced cross-priming of cytotoxic T cells as well as antitumor immunity were dependent on the host adapter protein MAVS and type I interferon (IFN-I) signaling and were mediated by dendritic cells. INTERPRETATION:Overall, our data demonstrate the potency of a novel combinatorial vaccination strategy combining RIG-I-driven immunization with CTLA-4 blockade to prevent and treat experimental melanoma. FUND: German Research Foundation (SFB 1335, SFB 1371), EMBO, Else Kröner-Fresenius-Foundation, German Cancer Aid, European Hematology Association, DKMS Foundation for Giving Life, Dres. Carl Maximilian and Carl Manfred Bayer-Foundation.

SUBMITTER: Heidegger S 

PROVIDER: S-EPMC6444128 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.

Heidegger Simon S   Kreppel Diana D   Bscheider Michael M   Stritzke Florian F   Nedelko Tatiana T   Wintges Alexander A   Bek Sarah S   Fischer Julius C JC   Graalmann Theresa T   Kalinke Ulrich U   Bassermann Florian F   Haas Tobias T   Poeck Hendrik H  

EBioMedicine 20190306


<h4>Background</h4>Antibody-mediated targeting of regulatory T cell receptors such as CTLA-4 enhances antitumor immune responses against several cancer entities including malignant melanoma. Yet, therapeutic success in patients remains variable underscoring the need for novel combinatorial approaches.<h4>Methods</h4>Here we established a vaccination strategy that combines engagement of the nucleic acid-sensing pattern recognition receptor RIG-I, antigen and CTLA-4 blockade. We used in vitro tran  ...[more]

Similar Datasets

| S-EPMC8131648 | biostudies-literature
| S-EPMC6478897 | biostudies-literature
| S-EPMC7097912 | biostudies-literature
| S-EPMC7904104 | biostudies-literature
| S-EPMC10079280 | biostudies-literature
| S-EPMC7523436 | biostudies-literature
2024-07-10 | GSE234818 | GEO
| S-EPMC6267701 | biostudies-literature
| S-EPMC3587160 | biostudies-literature
| S-EPMC7484823 | biostudies-literature